NASDAQ:IKNA Ikena Oncology (IKNA) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free IKNA Stock Alerts $1.30 -0.01 (-0.76%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.28▼$1.3450-Day Range$1.24▼$1.6052-Week Range$1.02▼$7.64Volume122,140 shsAverage Volume226,860 shsMarket Capitalization$62.74 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Ikena Oncology alerts: Email Address Ikena Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside630.8% Upside$9.50 Price TargetShort InterestBearish5.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.50) to ($1.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 starsMedical Sector589th out of 913 stocksBiological Products, Except Diagnostic Industry95th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingIkena Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIkena Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.48% of the float of Ikena Oncology has been sold short.Short Interest Ratio / Days to CoverIkena Oncology has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ikena Oncology has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIkena Oncology does not currently pay a dividend.Dividend GrowthIkena Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKNA. Previous Next 0.8 News and Social Media Coverage News SentimentIkena Oncology has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ikena Oncology this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Ikena Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ikena Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.95% of the stock of Ikena Oncology is held by insiders.Percentage Held by Institutions75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ikena Oncology are expected to grow in the coming year, from ($1.50) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ikena Oncology is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ikena Oncology is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIkena Oncology has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Ikena Oncology Stock (NASDAQ:IKNA)Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More IKNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKNA Stock News HeadlinesApril 21, 2024 | finance.yahoo.comIkena Oncology, Inc. (IKNA)April 10, 2024 | globenewswire.comIkena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 19, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Ikena OncologyMarch 14, 2024 | finance.yahoo.comIkena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 13, 2024 | markets.businessinsider.comIkena Oncology’s Promising Drug Pipeline Merits a Buy RatingMarch 12, 2024 | benzinga.comIkena Oncology: Q4 Earnings InsightsMarch 12, 2024 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 12, 2024 | globenewswire.comIkena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comIkena Oncology to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 21, 2024 | finance.yahoo.comIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerFebruary 21, 2024 | globenewswire.comIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comDown -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a TurnaroundJanuary 24, 2024 | finance.yahoo.comDown -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a TurnaroundJanuary 22, 2024 | investing.comIkena Oncology Inc (IKNA)January 20, 2024 | benzinga.comIkena Oncology Stock (NASDAQ:IKNA) Dividends: History, Yield and DatesJanuary 19, 2024 | markets.businessinsider.comIkena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational ChangesJanuary 19, 2024 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Outlines Key Priorities and Provides Corporate UpdatesJanuary 18, 2024 | msn.comIkena to cut 35% of workforce, extend cash runway into 2H 2026January 18, 2024 | finance.yahoo.comIkena Oncology Outlines Key Priorities and Provides Corporate UpdatesNovember 11, 2023 | benzinga.comIkena Oncology Stock (NASDAQ:IKNA) Earnings Dates and Earning CallsNovember 11, 2023 | morningstar.comIkena Oncology Inc IKNANovember 10, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Adicet Bio (ACET), Biogen (BIIB) and Ikena Oncology (IKNA)November 10, 2023 | finance.yahoo.comBroker Revenue Forecasts For Ikena Oncology, Inc. (NASDAQ:IKNA) Are Surging HigherNovember 9, 2023 | marketwatch.comIkena Oncology Shares Slump to All-Time Low After IK-930 Cancer Drug DataNovember 9, 2023 | msn.comIkena tumbles after early data for lead asset, Q3 financialsSee More Headlines Receive IKNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IKNA CUSIPN/A CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees43Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+630.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,170,000.00 Net MarginsN/A Pretax Margin-745.94% Return on Equity-44.21% Return on Assets-37.27% Debt Debt-to-Equity RatioN/A Current Ratio12.58 Quick Ratio12.58 Sales & Book Value Annual Sales$9.16 million Price / Sales6.85 Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book0.37Miscellaneous Outstanding Shares48,260,000Free Float45,387,000Market Cap$62.74 million OptionableNot Optionable Beta0.33 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Mark Manfredi Ph.D. (Age 53)President, CEO & Director Comp: $803.9kDr. Jotin Marango M.D. (Age 45)Ph.D., CFO & Head of Corporate Development Comp: $581.42kMr. Bob LallySenior Vice President of Finance & OperationsMs. Srividya Subramanian Esq.Ph.D., VP & Deputy General CounselMs. Samantha VuksanicHead of Human ResourcesMr. Jeffrey Ecsedy Ph.D. (Age 54)Chief Development Officer Mr. Navin Parwani M.S.VP & Head of QualityMr. David Damphousse M.S.Senior Vice President of Clinical Development OperationsDr. Caroline Germa M.D. (Age 51)Chief Medical Officer Mr. Valdas Jurkauskas Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsGenenta ScienceNASDAQ:GNTAEntera BioNASDAQ:ENTXAligos TherapeuticsNASDAQ:ALGSInstil BioNASDAQ:TILElutiaNASDAQ:ELUTView All CompetitorsInstitutional OwnershipBVF Inc. ILBought 1,600,000 shares on 2/15/2024Ownership: 9.883%Vestal Point Capital LPBought 322,671 shares on 2/14/2024Ownership: 0.669%View All Institutional Transactions IKNA Stock Analysis - Frequently Asked Questions Should I buy or sell Ikena Oncology stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IKNA shares. View IKNA analyst ratings or view top-rated stocks. What is Ikena Oncology's stock price target for 2024? 3 Wall Street research analysts have issued 1-year target prices for Ikena Oncology's stock. Their IKNA share price targets range from $8.00 to $11.00. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 630.8% from the stock's current price. View analysts price targets for IKNA or view top-rated stocks among Wall Street analysts. How have IKNA shares performed in 2024? Ikena Oncology's stock was trading at $1.97 at the beginning of the year. Since then, IKNA stock has decreased by 34.0% and is now trading at $1.30. View the best growth stocks for 2024 here. Are investors shorting Ikena Oncology? Ikena Oncology saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,390,000 shares, an increase of 11.2% from the March 31st total of 1,250,000 shares. Based on an average daily trading volume, of 424,100 shares, the days-to-cover ratio is currently 3.3 days. Approximately 5.5% of the company's stock are short sold. View Ikena Oncology's Short Interest. When is Ikena Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our IKNA earnings forecast. How were Ikena Oncology's earnings last quarter? Ikena Oncology, Inc. (NASDAQ:IKNA) released its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). The firm earned $0.66 million during the quarter, compared to analyst estimates of $2.39 million. When did Ikena Oncology IPO? Ikena Oncology (IKNA) raised $125 million in an initial public offering on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO. How do I buy shares of Ikena Oncology? Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IKNA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
